Monitor for symptoms of neuropathy, primarily sensory. Neuropathy is cumulative, generally reversible and should be managed by dose adjustment and delays.

Peripheral Neuropathy induced by Ixempra

Peripheral neuropathy was common  

Patients treated with Ixempra should be monitored for symptoms of neuropathy, such as burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, or neuropathic pain. Neuropathy occurred early during treatment; ~75% of new onset or worsening neuropathy occurred during the first 3 cycles. Patients experiencing new or worsening symptoms may require a reduction or delay in the dose of Ixempra. In clinical studies, peripheral neuropathy was managed through dose reductions, dose delays, and treatment discontinuation. Neuropathy was the most frequent cause of treatment discontinuation due to drug toxicity.

March 2010, Jan M. Keppel Hesselin, MD, PhD